Research on the treatment of rifampin-susceptible tuberculosis-Time for a new approach

PLoS Med. 2024 Jul 25;21(7):e1004438. doi: 10.1371/journal.pmed.1004438. eCollection 2024 Jul.

Abstract

In the Perspective, William Burman and colleagues advocate improving the safety and acceptability of treatment, rather than treatment-shortening, of rifampin-susceptible tuberculosis.

MeSH terms

  • Antitubercular Agents* / adverse effects
  • Antitubercular Agents* / therapeutic use
  • Humans
  • Mycobacterium tuberculosis / drug effects
  • Rifampin* / therapeutic use
  • Tuberculosis* / drug therapy

Substances

  • Rifampin
  • Antitubercular Agents

Grants and funding

The author(s) received no specific funding for this work.